AbCellera Biologics Inc (ABCL)
3.865
-0.04
(-1.15%)
USD |
NASDAQ |
Apr 19, 16:00
3.87
0.00 (0.00%)
After-Hours: 20:00
AbCellera Biologics Free Cash Flow (Quarterly): -34.04M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -34.04M |
| September 30, 2023 | -21.00M |
| June 30, 2023 | -7.298M |
| March 31, 2023 | -59.05M |
| December 31, 2022 | 18.58M |
| September 30, 2022 | -141.30M |
| June 30, 2022 | 241.69M |
| March 31, 2022 | 85.72M |
| Date | Value |
|---|---|
| December 31, 2021 | -26.14M |
| September 30, 2021 | -14.51M |
| June 30, 2021 | 120.88M |
| March 31, 2021 | 105.90M |
| December 31, 2020 | -0.224M |
| September 30, 2020 | -7.686M |
| June 30, 2020 | 22.27M |
| March 31, 2020 | -6.347M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-141.30M
Minimum
Sep 2022
241.69M
Maximum
Jun 2022
17.34M
Average
-6.822M
Median
Free Cash Flow (Quarterly) Benchmarks
| Acasti Pharma Inc | -1.892M |
| Aurinia Pharmaceuticals Inc | 14.25M |
| Edesa Biotech Inc | -1.406M |
| Lexaria Bioscience Corp | -0.6766M |
| InMed Pharmaceuticals Inc | -1.857M |